Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-acetylcysteine for prevention of inflammatory and oxidative lung changes after asbestos exposure
ACTRN12609000818235Phase 3Completed
- Sponsor
- The University of Western Australia
- Start
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of acetylcysteine in Asbestos-related lung disease (ARLD) (2 arms), sponsored by The University of Western Australia. Primary endpoints: Exhaled breath condensate F2-isoprostane, Blood markers of oxidative stress and 1 more. Started May 2010; status: completed.
02
Drugs
acetylcysteine
03
Conditions
Asbestos-related lung disease (ARLD)
Beyond the preview
Go deeper on ACTRN12609000818235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000818235.